BFC Planning’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RXRX
BFC Planning's RXRX Position: Q3 2026 in Review
BFC Planning reduced its Recursion Pharmaceuticals (RXRX) stake by 68% in Q3 2026, selling an estimated $19.3K and leaving 2,697 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2324.
BFC Planning first reported a position in RXRX in Q3 2024 and has held it in 9 quarters since. The position peaked at $42.4K in Q3 2025. 272 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.
- BFC Planning held 2,697 shares of Recursion Pharmaceuticals worth $11.1K as of Q3 2026.
- BFC Planning sold 5,702 Recursion Pharmaceuticals shares in Q3 2026, an estimated $19.3K.
- Recursion Pharmaceuticals made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2324 holding.
- BFC Planning first reported a position in Recursion Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
- BFC Planning's Recursion Pharmaceuticals position peaked at $42.4K in Q3 2025.
- 272 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.